Burden of bone disease
Burden of bone disease
复制标题
DOI：
10.1016/j.ejon.2007.07.002
复制
发表时间：
2007-01-01
影响因子：
2.8
通讯作者：
Kinnane, Nicole
中科院分区：
文献类型：
--
作者：
Kinnane, Nicole
目的：恶性骨病可引起临床相关的骨骼发病，对生活质量产生负面影响。将讨论骨转移引起的骨骼相关事件 (SRE) 的患病率和后果，以及骨转移治疗的效果。方法：通过 PubMed 和国际肿瘤学会议记录研究骨疾病的负担。结果：恶性骨疾病是一种潜在的破坏性疾病，在晚期癌症患者中普遍存在。大多数骨转移患者至少经历过 1 次 SRE，这可能会降低生存率并显着增加医疗费用。骨痛是这些患者严重疼痛的最常见原因，通常可以通过镇痛药或放疗来控制。然而，由于相关的副作用，治疗可能很困难。双膦酸盐可以缓解骨痛，并可以治疗症状的根本原因：恶性骨病。预防或延迟 SRE 的发生至关重要，因为患有 SRE 的患者发生额外 SRE 的风险增加，从而降低生活质量。结论：转移性骨病给患者和社会带来巨大负担。唑来膦酸支持治疗已显示出对骨转移患者的益处，可以延迟 SRE 的发病并降低 SRE 的发生率，从而保持患者的生活质量和功能独立性。 (C) 2007 年，爱思唯尔有限公司出版。
Objectives: Malignant bone disease can cause clinically relevant skeletal morbidity that negatively affects quality of life. The prevalence and consequences of skeletal-related events (SREs) resulting from bone metastases, and the effects of bone metastasis therapies will be discussed.Methods: The burden of bone disease was researched through PubMed and the proceedings of international oncology meetings.Results: Malignant bone disease is a potentially devastating condition that is prevalent in patients with advanced cancers. Most patients with bone metastases experience at least 1 SRE, which may reduce survival and add considerably to healthcare costs. Bone pain, the most common source of severe pain in these patients, can often be managed with analgesics or radiotherapy. However, treatment may be difficult because of associated side effects. Bisphosphonates palliate bone pain and can treat the underlying cause of the symptoms: malignant osteotysis. Preventing or delaying the onset of SREs is crucial because patients with an SRE have an increased risk of additional SREs, thereby reducing quality of life.Conclusions: Metastatic bone disease is a tremendous burden on patients and society. Supportive therapy with zoledronic acid has shown benefits for patients with bone metastases by delaying the onset and reducing the incidence of SREs, thus preserving patients' quality of life and functional independence. (C) 2007 Published by Elsevier Ltd.